Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Study of BMS-986012 in Subjects With Small Cell Lung Caner

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: BMS-986012
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2016-10-31

Last Posted Date: 2019-08-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT02949895

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Radiation: hypofractionated radiotherapy
Drug: Pemetrexed
Drug: Etoposide

First Posted Date: 2016-10-27

Last Posted Date: 2017-11-30

Lead Sponsor: The Netherlands Cancer Institute

Registration Number: NCT02947113

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

Phase 2

Terminated

Conditions: Small Cell Lung Cancer (SCLC)

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Radiation: Radiation therapy

First Posted Date: 2016-10-17

Last Posted Date: 2021-11-16

Lead Sponsor: NYU Langone Health

Target Recruit Count: 5

Registration Number: NCT02934503

Locations: 🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

L-DEP as an Initial Treatment for EBV-HLH

Phase 3

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Pegaspargase
Drug: doxorubicin hydrochloride liposome injection
Drug: dexamethasone
Drug: Etoposide
Drug: methylprednisolone

First Posted Date: 2016-09-23

Last Posted Date: 2016-09-23

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 120

Registration Number: NCT02912702

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors

Early Phase 1

Recruiting

Conditions: Brain Tumor Recurrent

Interventions: Drug: Methotrexate
Drug: Etoposide
Procedure: Ommaya Reservoir

First Posted Date: 2016-09-19

Last Posted Date: 2024-05-08

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 10

Registration Number: NCT02905110

Locations: 🇺🇸
UTHealth & Children's Memorial Hermann Hospital, Houston, Texas, United States

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Extensive Stage Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cediranib
Drug: Cediranib Maleate
Drug: Cisplatin
Drug: Etoposide
Drug: Olaparib

First Posted Date: 2016-09-14

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT02899728

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 21 locations

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Dexamethasone
Drug: Aracytine
Drug: Cisplatinum
Drug: Etoposide
Drug: Melphalan
Drug: Carmustine

First Posted Date: 2016-09-12

Last Posted Date: 2024-03-15

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 86

Registration Number: NCT02896582

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
CHU d'Amiens, Amiens, France
🇫🇷
CH d'Avignon, Avignon, France

and more 27 locations

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

First Posted Date: 2016-08-30

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5949

Registration Number: NCT02883049

Locations: 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 236 locations